CREBBP and acute lymphoblastic leukemia: Finally, we sought to test whether Venetoclax could target CREBBP-mutated B-ALL in-vivo, where cell extrinsic factors and pharmacodynamic effects can result in reduced efficacy or highlight dose-limiting toxicities.